Back to All Resources

The MDM2 degrader KTX-049 is highly potent in TP53 wild-type (p53 WT) Merkel cell carcinoma (MCC)

October 14, 2023

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

Kymera AACR NCI EORTC October 2023 Picture
View Poster
Area of Focus
Oncology
Programs
MDM2 (KT-253)
Indications
Solid Tumors
Development Stage
Pre-clinical Data
Share
LinkedInXFacebookEmailCopy Link

You may also be interested in these resources

June 6, 2023
Pulse Dosing of Potent and Selective Heterobifunctional MDM2 Degrader KT-253 Drives Tumor Regression and Demonstrates Differentiated Pharmacology Compared to p53/MDM2 Small Molecule Inhibitors
European Hematology Association (EHA) 2023 Hybrid Congress
Liquid Tumors
View Resource
December 11, 2022
Development of KT-253, a Highly Potent and Selective Heterobifunctional MDM2 Degrader for the treatment of Acute Myeloid Leukemia
American Society of Hematology Annual Meeting
Liquid Tumors
View Resource